ITRM
Iterum Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.87 / 10
Netural
Capital flows are positive (7.73/10), evidenced by strong overall, block, medium, and extra-large inflows, despite small and large outflows. Analyst sentiment is limited to one provider (HC Wainwright & Co.) but is unanimously 'Strong Buy'. The combination of robust fund inflows and bullish analyst view offsets some technical weakness, yet the overall rating remains neutral due to mixed fundamentals and poor technical posture.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-05-08
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of ITRM?
- ITRM holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.87/10 (Netural).
